secwatch.observer — SEC 8-K summary ====================================== Issuer: CG Oncology, Inc. (CGON) CIK: 0001991792 Form: 8-K Filed at: 2026-11-16T13:15:21+00:00 Accession: 0001193125-26-462199 Event type: other_material Sentiment: positive Materiality: 0.90 Item codes: 7.01, 8.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 CG Oncology PIVOT-006 Phase 3 wins: 68% recurrence risk cut (HR 0.32) in NMIBC ------------------------------------------------------------------------------ - Cretostimogene cut recurrence risk 68% vs control in adjuvant intermediate-risk/high-grade Ta ≤3cm NMIBC; HR 0.32 (95% CI 0.23-0.45; p<0.0001), median follow-up 17 months. - No Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations; safety consistent with prior studies. - Initial BLA in BCG-unresponsive NMIBC broadened per FDA feedback to include high-grade papillary-only disease plus CIS; completion now expected by end of March 2027. - Second BLA in intermediate-risk and high-grade Ta NMIBC planned for Q2 2027; ~50,000 US patients in this population have no FDA-approved adjuvant option. - Topline results to be presented as a late-breaking podium at the Society of Urologic Oncology Annual Meeting on December 2, 2026. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312526462199/0001193125-26-462199-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1991792/000119312526462199/ck0001991792-20261116.htm HTML page: https://secwatch.observer/filing/0001193125-26-462199 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer